Capturing New Drugs That Selectively Modulate PAR2 Signaling Pathways
Funder
National Health and Medical Research Council
Funding Amount
$469,088.00
Summary
Infection and tissue damage provoke acute inflammatory responses that sometimes continue unchecked, leading to different kinds of debilitating inflammatory diseases and cancers. We have discovered a new class of drugs that bind to a new target on human cells and block undesirable prolonged inflammatory responses. This project tests a new strategy to produce 'cleaner' drugs that act more selectively with fewer side effects against a new target in the treatment of arthritis and other inflammatory ....Infection and tissue damage provoke acute inflammatory responses that sometimes continue unchecked, leading to different kinds of debilitating inflammatory diseases and cancers. We have discovered a new class of drugs that bind to a new target on human cells and block undesirable prolonged inflammatory responses. This project tests a new strategy to produce 'cleaner' drugs that act more selectively with fewer side effects against a new target in the treatment of arthritis and other inflammatory diseases, diet-induced obesity and cancers.Read moreRead less
Development Of Reversible Inhibitors Of Factor XIa
Funder
National Health and Medical Research Council
Funding Amount
$444,318.00
Summary
Blood usually clots in response to injury, but unwanted clots can cause thrombosis, as well as leading to stroke and heart disease. Existing drugs to treat thrombosis suffer from drawbacks such as invasive monitoring, interaction with diet and other medicines, and bleeding complications. New drugs are clearly needed. Our expert group of researchers will discover new anti-thrombotic compounds based upon our previous identification of natural products with anticoagulant properties.